SERVICES

Archive | Drugs and Pharmaceuticals

Caption: Mark Whitacre

Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him

FRESNO, Calif., March 25 (SEND2PRESS NEWSWIRE) — Cypress Systems, Inc., a Fresno CA based biotechnology company, announced that it has promoted Mark E. Whitacre, Ph.D. to become the company’s Chief Operating Officer (COO) and President of Operations. Dr. Whitacre joined the executive management team in December 2006 as President of Technology and Business Development for […]

Continue Reading

deverus, Inc. Partners with eScreen Inc. to Offer First and Only Instrumented Instant Drug Testing Device to Clients

AUSTIN, Texas – Jan. 4 (SEND2PRESS NEWSWIRE) — deverus, Inc., the leader in background screening technology, recently announced a partnership with eScreen Inc., a company known for its innovative drug screening technology. After comparing different providers, deverus found that no one could match the selection and quality of products that eScreen had to offer. Through […]

Continue Reading
(c) Send2Press

Ophthalmic Research and Development Company Launches Adjunctive Eyelid Therapy and Hygiene Product

RICHMOND, Texas – Aug. 6 (SEND2PRESS NEWSWIRE) — CYNACON /OCuSOFT(R) (OCuSOFT, Inc.) specializes in ophthalmic research, development and supply to ophthalmologists and optometrists. They are excited to announce a new and innovative prescription-only ALODOX(R) Convenience Kit for adjunctive eyelid therapy and hygiene.

Continue Reading
(c) Send2Press

U.S. Pharmaceuticals Spend $8 Billion Annually in R&D Conducted Overseas – New Clintelligence(R) Alignment Module Advances Global Management

KENILWORTH, N.J. – June 12 (SEND2PRESS NEWSWIRE) — 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announces today the release of a new module to its highly successful Clintelligence(R) Business Intelligence Solution.

Continue Reading
(c) Send2Press

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

SAN MARINO, Calif. – June 4 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour – published in the June issue of the International […]

Continue Reading
(c) Send2Press

Epeius Biotechnologies Reaches Out to American Cancer Patients, Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma

SAN MARINO, Calif. – June 4 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, […]

Continue Reading
(c) Send2Press

Drug Development Costs Exceed $802 Million: Global Pharmas Use Clintelligence to Do Something About It

KENILWORTH, N.J. – May 2, 2007 (SEND2PRESS NEWSWIRE) — 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announced today that it has aligned with yet another Global Pharmaceutical Firm to implement Clintelligence – 3C Company’s Business Intelligence Solution for strategic and tactical oversight of their Research […]

Continue Reading
(c) Send2Press

Tired… Distressed… Unhappy? All Natural ‘Feel Good’ Pill Strikes a Chord with Millions of Women

SALT LAKE CITY, Utah – Apr. 26 (SEND2PRESS NEWSWIRE) — This provocative opening line from a television commercial for a ‘mood elevating’ pill has really struck a nerve. If the overwhelming response to the Libutol(TM) ad is any indication, it seems American women are more tired, distressed and unhappy than most experts (and women themselves) […]

Continue Reading

	 SAN MARINO, CA - Apr. 7 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G(TM), the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer. Following the landmark approval of Rexin-G(TM) for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila.

Expanded Access Program for Rexin-G Provides Genetic Medicine to Cancer Patients, First Revenues for Epeius Biotechnologies

SAN MARINO, CA – Apr. 7 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G(TM), the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer. Following the landmark approval of Rexin-G(TM) for the treatment of all […]

Continue Reading

Part of the Neotrope® News Network, USA. Neotrope.net